Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn’s Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study

BACKGROUND AND AIMS: The objective was to evaluate the pharmacokinetics, safety/tolerability, and efficacy of ustekinumab in children with moderately to severely active Crohn’s disease. METHODS: In this Phase 1, multicentre, 16-week, double-blind, induction dose-ranging study [NCT02968108], patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosh, Joel R, Turner, Dan, Griffiths, Anne, Cohen, Stanley A, Jacobstein, Douglas, Adedokun, Omoniyi J, Padgett, Lakshmi, Terry, Natalie A, O’Brien, Christopher, Hyams, Jeffrey S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575045/
https://www.ncbi.nlm.nih.gov/pubmed/34037715
http://dx.doi.org/10.1093/ecco-jcc/jjab089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8575045/
https://www.ncbi.nlm.nih.gov/pubmed/34037715
http://dx.doi.org/10.1093/ecco-jcc/jjab089

Ejemplares similares